Literature DB >> 24672116

Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey.

Adam Keller Ashton1, Brenda D Jamerson2, Wendy L Weinstein1, Christine Wagoner3.   

Abstract

BACKGROUND: Despite the high prevalence of depression in the United States, 10 few studies have identified which adverse effects (AEs) patients are willing or unwilling to tolerate when receiving antidepressants.
OBJECTIVE: The aim of this study was to identify reasons for discontinuation10 and noncompliance with antidepressant medications, the impact of AEs on compliance and quality of life (assessed using impact of AEs on activities of daily living), and patients' suggestions for improving their medication, using a patient survey.
METHODS: Patients aged 18 to 65 years with mild to severe depression were 10 randomly selected by their physicians to be sent an invitation to complete the 42-question survey. Three hundred physicians nationwide assessed the severity of depression and symptoms of anxiety in each respondent, using their judgment. Patients were asked specific questions to assess reasons for discontinuation/noncompliance. Patients were also asked to rate AEs based on how difficult they were to "live with," and what 2 aspects of their antidepressant medication they would change if they could.
RESULTS: In a separate, concurrent study, physicians classified 175 (50%) abd
Results: 0 mildly to moderately depressed and 84 (24%) as severely depressed. Ninety-one respondents (26%) were classified as having symptoms of anxiety. Two hundred seven patients (60%) indicated they had discontinued treatment with an antidepressant agent at some point in their lives, the most common reason for which was lack of efficacy (92 patients [44%]). Of the 344 patients currently being treated with an antidepressant, 75 (22%) reported noncompliance. The most common reasons for noncompliance were "have trouble remembering to take it" (19/44 patients [43%]), "gained a lot of weight" (11/41 [27%]), "unable to have an orgasm" (8/40 [20%]), and "lost interest in sex" (8/41 [20%]). The 4 AEs patients expressed as "extremely difficult to live with" were "weight gain" (104 patients [31%]), "unable to have erection" (83 [25%]), "difficulty reaching orgasm" (80 [24%]), and "tired during the day/no energy" (69 patients [21%]). The 3 most frequently cited improvements patients (n = 327) would make to their medications were better efficacy (176 patients [54%]) and eliminating AEs related to sexual desire and weight gain (112 [34%] and 105 [32%] patients, respectively).
CONCLUSIONS: The findings of this survey of patients with mild to severe10 depression suggest that compliance, and hence efficacy, can be promoted by (1) understanding what patients expect and desire from the antidepressants they are prescribed and (2) prescribing antidepressants associated with low rates of weight gain, sexual dysfunction, or tiredness.

Entities:  

Keywords:  antidepressants; discontinuation; noncompliance; tolerability

Year:  2005        PMID: 24672116      PMCID: PMC3964563          DOI: 10.1016/j.curtheres.2005.04.006

Source DB:  PubMed          Journal:  Curr Ther Res Clin Exp        ISSN: 0011-393X


  18 in total

1.  Effects of physician communication style on client medication beliefs and adherence with antidepressant treatment.

Authors:  D C Bultman; B L Svarstad
Journal:  Patient Educ Couns       Date:  2000-05

2.  Determinants of antidepressant treatment compliance: implications for policy.

Authors:  M Tai-Seale; T W Croghan; R Obenchain
Journal:  Med Care Res Rev       Date:  2000-12       Impact factor: 3.929

3.  A systematic review of the associations between dose regimens and medication compliance.

Authors:  A J Claxton; J Cramer; C Pierce
Journal:  Clin Ther       Date:  2001-08       Impact factor: 3.393

Review 4.  Compliance with medication regimens for mental and physical disorders.

Authors:  J A Cramer; R Rosenheck
Journal:  Psychiatr Serv       Date:  1998-02       Impact factor: 3.084

5.  Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events.

Authors:  K Demyttenaere; P Enzlin; W Dewé; B Boulanger; J De Bie; W De Troyer; P Mesters
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

Review 6.  Enhancing patient outcomes: treatment adherence.

Authors:  E Frank
Journal:  J Clin Psychiatry       Date:  1997       Impact factor: 4.384

7.  Patient compliance in depression. Based on a presentation by James Jefferson, MD.

Authors: 
Journal:  Am J Manag Care       Date:  2000-02       Impact factor: 2.229

Review 8.  Approaches to the enhancement of patient adherence to antidepressant medication treatment.

Authors:  P L Delgado
Journal:  J Clin Psychiatry       Date:  2000       Impact factor: 4.384

Review 9.  Clinical issues in long-term treatment with antidepressants.

Authors:  J M Zajecka
Journal:  J Clin Psychiatry       Date:  2000       Impact factor: 4.384

10.  Compliance and acceptance in antidepressant treatment.

Authors:  K Demyttenaere
Journal:  Int J Psychiatry Clin Pract       Date:  2001       Impact factor: 1.812

View more
  31 in total

1.  The Safety and Tolerability Profile of Vilazodone, A Novel Antidepressant for the Treatment of Major Depressive Disorder.

Authors:  Michael Liebowitz; Harry A Croft; Daniel K Kajdasz; Heidi Whalen; Susan Gallipoli; Maria Athanasiou; Carol R Reed
Journal:  Psychopharmacol Bull       Date:  2011-09-15

Review 2.  Lessons learned from placebo groups in antidepressant trials.

Authors:  Meike Shedden Mora; Yvonne Nestoriuc; Winfried Rief
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-06-27       Impact factor: 6.237

3.  Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs.

Authors:  Jonathan R T Davidson; Douglas E Feltner; Ashish Dugar
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

4.  Drug-Induced Sexual Dysfunction: An Analysis of Reports to a National Pharmacovigilance Database.

Authors:  Carolina Valeiro; Cristiano Matos; Joep Scholl; Florence van Hunsel
Journal:  Drug Saf       Date:  2022-04-07       Impact factor: 5.606

5.  Predicting Medication Nonadherence in Older Adults With Difficult-to-Treat Depression in the IRL-GRey Randomized Controlled Trial.

Authors:  Helene M Altmann; Joseph Kazan; Marie Anne Gebara; Daniel M Blumberger; Jordan F Karp; Eric J Lenze; Benoit H Mulsant; Charles F Reynolds; Sarah T Stahl
Journal:  Am J Geriatr Psychiatry       Date:  2022-03-10       Impact factor: 7.996

6.  Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study.

Authors:  David V Sheehan; Harry A Croft; E Roderich Gossen; Randy J Levitt; Claire Brullé; Sylvie Bouchard; Anna Rozova
Journal:  Psychiatry (Edgmont)       Date:  2009-05

Review 7.  Changes in body weight and psychotropic drugs: a systematic synthesis of the literature.

Authors:  Robert Dent; Angelique Blackmore; Joan Peterson; Rami Habib; Gary Peter Kay; Alan Gervais; Valerie Taylor; George Wells
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240

8.  Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial.

Authors:  Anita H Clayton; Carl Gommoll; Dalei Chen; Rene Nunez; Maju Mathews
Journal:  Int Clin Psychopharmacol       Date:  2015-07       Impact factor: 1.659

9.  An estimation of patients at potential risk for drug-induced sexual dysfunction using pharmacy dispensing data.

Authors:  Rineke Gordijn; Melianthe P J Nicolai; Henk W Elzevier; Henk-Jan Guchelaar; Martina Teichert
Journal:  Fam Pract       Date:  2021-06-17       Impact factor: 2.267

10.  Multi-modality: a new approach for the treatment of major depressive disorder.

Authors:  Elliott Richelson
Journal:  Int J Neuropsychopharmacol       Date:  2013-01-30       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.